menu search

Intra-cellular (itci) q3 earnings top, product sales view raised

Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. caplyta sales continue t...

November 3, 2023, 1:32 pm

Intra-cellular therapies reports third quarter 2023 financial results and raises 2023 caplyta sales guidance

Q3 2023 total revenues increased to $126.2 million, compared to $71.9 million in the same period in 2022 caply...

November 2, 2023, 11:30 am

Intra-cellular therapies: caplyta's rise and a promising pipeline

Intra-Cellular Therapies' main drug, caplyta, has been successful in treating neuropsychiatric conditio...

August 12, 2023, 10:29 am

Intra-cellular (itci) q2 earnings & sales top, '23 view raised

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. caplyta sales continue to dr...

August 4, 2023, 9:47 am

Intra-cellular therapies: depression data boosts investment prospects (rating upgrade)

Intra-Cellular's drug caplyta (lumateperone) is advancing through trials for major depressive disorder ...

May 25, 2023, 7:51 pm

Why intra-cellular therapies climbed tuesday

caplyta, the company's lead drug, was responsible for most of the company's revenue in 2022. The potent...

March 28, 2023, 12:27 pm

Intra-cellular (itci) q4 earnings & sales top, caplyta shines

Intra-Cellular Therapeutics (ITCI) reports a better-than-expected financial performance in the fourth quarter of 2022 as both earnings and revenues be...

March 2, 2023, 9:47 am

Intra-cellular: hitting a growth inflection (rating upgrade)

Following approval for schizophrenia in late 2019, caplyta then gained its first label expansion for bi...

December 18, 2022, 9:30 am

Intra-cellular's (itci) caplyta aids growth, overdependence a woe

Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, caplyta, a...

November 18, 2022, 3:11 pm

Robust uptake of antipsychotic drug boosts intra-cellular's q1 earnings

Intra-Cellular Therapies Inc's (NASDAQ: ITCI) Q1 revenues reached $35.0 million, compared to $15.9 million a year ago, beating the consensus of $33....

May 10, 2022, 3:04 pm

Intra-cellular; long-term to own with a few fda approvals and ability to expand

caplyta has been approved by the FDA for the treatment of adults with schizophrenia and adults with bip...

March 8, 2022, 3:09 pm


Search within

Pages Search Results: